Long-term outcomes in patients with PET-predicted poor-responsive HER2-positive breast cancer treated with neoadjuvant bevacizumab added to trastuzumab and docetaxel: 5-year follow-up of the randomised Avataxher study

BACKGROUND: The open-label, randomised Phase 2 AVATAXHER study (NCT01142778) demonstrated that early PET assessment identified HER2-positive breast cancer patients who responded poorly to neoadjuvant docetaxel plus trastuzumab. Adding neoadjuvant bevacizumab for PET-predicted poor-responders improve...

Descripción completa

Detalles Bibliográficos
Autores principales: Coudert, Bruno, Pierga, Jean-Yves, Mouret-Reynier, Marie-Ange, Kerrou, Kaldoun, Ferrero, Jean-Marc, Petit, Thierry, Du, Fanny Le, Dupré, Pierre-François, Bachelot, Thomas, Gabelle, Philippe, Chauvet, Marie-Pierre, Coeffic, David, Barbe, Catherine, Prevost, Jean-Briac, Paintaud, Gilles, Thibault, Gilles, Ferhat, Abdennour, Dupin, Julien, Berriolo-Riedinger, Alina, Arnould, Laurent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649610/
https://www.ncbi.nlm.nih.gov/pubmed/33205032
http://dx.doi.org/10.1016/j.eclinm.2020.100566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7649610/
https://www.ncbi.nlm.nih.gov/pubmed/33205032
http://dx.doi.org/10.1016/j.eclinm.2020.100566

Ejemplares similares